About Applied Therapeutics, Inc. - Common Stock (APLT)
Applied Therapeutics Inc. is a biotechnology company focused on developing innovative treatments for patients with serious and chronic diseases, particularly those with unmet medical needs. The company's research emphasizes the discovery and advancement of therapeutics that target underlying disease mechanisms, with a primary focus on conditions such as diabetic complications and other metabolic disorders. Applied Therapeutics aims to leverage its expertise in chemistry and biology to bring effective solutions to the market, enhancing patient outcomes and addressing critical health challenges. Through its dedication to scientific rigor and the development of novel compounds, the company strives to make a meaningful impact in the field of medicine. Read More
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
- Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting
Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension
- Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice President and Head of Quality
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission (“SEC”) related to the Company’s Annual Report on Form 10-K for the fiscal year 2024 (the “Form 10-K”). Form 12b-25 will allow the Company an automatic extension of 15 additional calendar days to file the Form 10-K for the fiscal year 2024, which is due on March 31, 2025. The Company is working diligently to finalize its financial statements and currently expects to file its Annual Report on Form 10-K as soon as practicable by April 15, 2025, the end of the 15-day extension period, in accordance with Rule 12b-25.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) and reminds investors of the February 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
RADNOR, PA - February 18, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Applied Therapeutics, Inc. (“Applied Therapeutics”) (NASDAQ: APLT) on behalf of those who purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024, and December 2, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 18, 2025.
RADNOR, PA - February 17, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Applied Therapeutics, Inc. (“Applied Therapeutics”) (NASDAQ: APLT) on behalf of those who purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024, and December 2, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 18, 2025.
NEW YORK - February 17, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) on behalf of investors that purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024 and December 2, 2024 (the “Class Period”).
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024. Applied Therapeutics is a clinical-stage biopharmaceutical company.
RADNOR, PA - February 15, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Applied Therapeutics, Inc. (“Applied Therapeutics”) (NASDAQ: APLT) on behalf of those who purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024, and December 2, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 18, 2025.
NEW YORK - February 15, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) on behalf of investors that purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024 and December 2, 2024 (the “Class Period”).
The Law Offices of Frank R. Cruz reminds investors of the upcoming February 18, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, inclusive (the “Class Period”).
NEW YORK - February 14, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) on behalf of investors that purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024 and December 2, 2024 (the “Class Period”).
